☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
astellas pharma
The NMPA Approves Astellas’ Padcev (Enfortumab vedotin) to Treat Adults with Advanced or Metastatic Urothelial Cancer
August 20, 2024
Astellas Receives the MHLW’s Priority Review for the sNDA Submitted for Padcev and Keytruda as Combination Therapy to Treat Bladde...
February 16, 2024
Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue
August 9, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.